Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6811 to 6825 of 8901 results

  1. Hernia

    Discontinued Reference number: GID-CGWAVE0771

    NICE guideline
    Discontinued

  2. Diagnostic services

    Discontinued Reference number: GID-CGWAVE0773

    NICE guideline
    Discontinued

  3. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

    NICE guideline
    Discontinued

  4. MRI guided focussed ultrasound for chronic pain

    Discontinued Reference number: GID-IP1043

    Interventional procedures guidance
    Discontinued

  5. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

    Technology appraisal guidance
    Discontinued

  6. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development Reference number: GID-TA11400 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]

    In development Reference number: GID-TA11831 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]

    In development Reference number: GID-TA11368 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    Discontinued Reference number: GID-TA11655

    Technology appraisal guidance
    Discontinued

  11. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]

    In development Reference number: GID-TA11372 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    In development Reference number: GID-TA10895 Expected publication date:  29 October 2026

    Technology appraisal guidance
    In development

  13. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    In development Reference number: GID-TA11367 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development Reference number: GID-TA11117 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

    Technology appraisal guidance
    In development